Title: Compositions and Methods for Treating Trail-Resistant Cancer Cells. Number: 20040126791. Filed: Sept. 19, 2003. Lead Inventor: Harald Wajant, Ribopharma (Alnylam).
The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of a cellular FLICE-like inhibitory protein gene, comprising a complementary RNA strand [that] is substantially identical to at least a part of a cFLIP gene.”
The abstract adds that the invention also relates “to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for inhibiting the expression of a cFLIP gene in a cell, methods for improving the effectiveness of an apoptosis-inducing drug, and methods for treating cancer using the pharmaceutical composition.”
Title: Colon Carcinoma-Related Oligonucleotides and Methods of Use. Number: 20040127450. Filed: Jan. 12, 2004. Inventor: Ramaswamy Narayanan, Florida Atlantic University.
According to the patent application’s abstract, the invention relates to “synthetic oligonucleotides (antisense, ribozymes, siRNA, and triple helix molecules) useful in down-regulating expression of a colon carcinoma-related gene nucleic acid or protein in a cell; and treatment method using said oligonucleotides alone or in combination with chemotherapy or radiation therapy.”